Tesamorelin Dosage Protocol Guide for Research 2026 — Reconstitution, Dosing & GH Secretagogue Research

# Tesamorelin Dosage Protocol Guide for Research 2026 — Reconstitution, Dosing & GH Secretagogue Research

References

• •PMID: 42538058
• •PMID: 42395176
• •PMID: 42382101

> Research Use Only (RUO) Disclaimer: All information in this article is intended exclusively for licensed researchers and scientific professionals operating within approved laboratory and institutional frameworks. Tesamorelin is an FDA-approved prescription drug (Egrifta SV/Egrifta WR) indicated only for HIV-associated lipodystrophy. Any use outside that indication requires a valid prescription and physician oversight. This article does not constitute medical advice, clinical guidance, or an endorsement of self-administration. Peptides.SO is a research information platform only.

---

What Is Tesamorelin?

Tesamorelin is a 44-amino acid synthetic analog of endogenous growth hormone-releasing hormone (GHRH), modified with a trans-3-hexenoic acid moiety at the N-terminus. That structural addition blocks dipeptidyl peptidase-IV (DPP-IV) enzymatic cleavage — the same mechanism that degrades native GHRH within minutes of release — extending tesamorelin's effective plasma half-life to approximately 26–38 minutes versus sermorelin's ~10–20 minutes.

The result: tesamorelin generates a more sustained GHRH receptor engagement, triggering a stronger, more reproducible GH pulse from anterior pituitary somatotroph cells. This makes it approximately 40-fold more potent than sermorelin on a molar basis.

Commercially, tesamorelin is sold as:

• •Egrifta SV — the current standard-of-care brand (2 mg/day, daily reconstitution)
• •Egrifta WR — a newer formulation approved March 2025 (1.28 mg/day, weekly reconstitution)

Both are manufactured by Theratechnologies. For a broader comparison across the GHRH analog class, see our GHRH Analogs Compared overview.

---

Mechanism of Action: GHRH Receptor Agonism and Pulsatile GH Release

Tesamorelin binds to and activates the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells — the same G-protein coupled receptor activated by endogenous GHRH. The downstream cascade:

1. GHRHR activation → cAMP rise → PKA activation → CREB phosphorylation

2. GH gene transcription → somatotroph GH synthesis

3. Pulsatile GH secretion into portal circulation

4. Hepatic IGF-1 synthesis → circulating IGF-1 elevation (mean +70 ng/mL in Phase III)

5. Peripheral IGF-1 signaling → lipolysis in visceral adipocytes, lean mass preservation

Unlike direct GH administration, tesamorelin preserves the negative feedback loop: elevated IGF-1 suppresses hypothalamic GHRH release, preventing runaway GH elevation. This feedback preservation is what makes tesamorelin's GH pulse pattern more physiological than exogenous GH injection — and is hypothesized to explain its selective visceral fat effect vs. subcutaneous fat.

The N-terminal trans-3-hexenoyl modification that distinguishes tesamorelin from native GHRH(1–44) prevents DPP-IV cleavage at the Ala2-Asp3 bond, extending the functional plasma half-life and ensuring sustained receptor engagement during the daily dosing window.

---

Why Researchers Study Tesamorelin Beyond HIV Lipodystrophy

Tesamorelin's FDA approval covers one narrow indication: HIV-associated lipodystrophy — the visceral fat redistribution caused by long-term antiretroviral therapy. But the compound's mechanism generates broader scientific interest:

1. Selective Visceral Adiposity Reduction

Unlike general weight-loss agents, tesamorelin reduces visceral adipose tissue (VAT) without meaningfully altering subcutaneous fat or BMI. This selectivity makes it a useful model compound for studying the mechanistic distinction between visceral and subcutaneous lipid metabolism.

2. Liver Fat Reduction (MASLD Research)

2023 ID Week data (Theratechnologies) and a 2024 PMC publication (PMID: PMC11365754) demonstrated that tesamorelin 2 mg/day produced a 31% relative reduction in hepatic fat fraction (HFF) versus 0% in placebo among HIV-positive patients on integrase inhibitor (INSTI)-based regimens over 12 months — raising interest in metabolic dysfunction-associated steatotic liver disease (MASLD) models.

3. Cognitive Research

A small body of work, including a trial by Sigalos & Pastuszak (2018), has examined whether GH-axis normalization via tesamorelin modulates cognitive function in aging populations. These investigations remain exploratory.

4. Lean Mass Preservation

Across Phase III datasets, tesamorelin treated subjects gained a mean 2–3 kg of lean mass concurrent with VAT reduction — a pattern distinguishing GHRH-analog GH stimulation from direct GH administration.

---

Reconstitution of Research-Grade Tesamorelin

> ⚠️ The following is a description of reconstitution procedures as documented in clinical trial protocols and the Egrifta prescribing information. It is presented for scientific context only.

For precise volume calculations during reconstitution, use the Peptides.SO reconstitution calculator to determine exact BAC water volumes and concentration targets for your specific vial size.

Supplies Needed

• •Tesamorelin lyophilized powder (1 mg or 2 mg vials, depending on formulation)
• •Sterile water for injection (SWFI) — not bacteriostatic water, per prescribing information
• •Insulin syringes (28–31 gauge, 1/2" needle recommended for subcutaneous delivery)
• •Alcohol swabs
• •Sharps disposal container

Step-by-Step Reconstitution (Egrifta SV — 1 mg/vial)

The approved daily dose is 2 mg, requiring two vials of Egrifta SV (each containing 1.1 mg lyophilized powder that reconstitutes to deliver 1 mg active drug in 0.5 mL SWFI).

1. Prepare workspace: Clean flat surface, wash hands, gather materials

2. Swab vial tops: Wipe rubber septum of both vials with an alcohol swab; allow to dry 30 seconds

3. Add SWFI to vial 1: Draw 0.5 mL SWFI into syringe; inject slowly into lyophilized vial 1 down the vial wall (do not jet directly onto the powder cake)

4. Roll, do not vortex: Gently roll the vial between palms 10–15 times; vortexing degrades peptide structure

5. Draw vial 1: Pull the reconstituted solution from vial 1 into the syringe

6. Inject into vial 2: Transfer the drawn solution from vial 1 into lyophilized vial 2 to reconstitute it using the same solution

7. Roll again: Roll vial 2 gently until fully dissolved (~15–30 seconds)

8. Withdraw final dose: Draw the complete 1 mL combined solution — this represents the 2 mg daily dose

9. Inspect: Solution should be clear, colorless to slightly yellow; discard if particulates, cloudiness, or discoloration are present

10. Administer immediately: Reconstituted tesamorelin is not stable for extended periods at room temperature

Egrifta WR Reconstitution (Weekly Format — 1.28 mg/day)

Egrifta WR (approved March 2025, commercially available September 2025) uses a concentrated 11.6 mg vial reconstituted with diluent once per week, providing 7 daily doses of 1.28 mg (0.16 mL each). Bioequivalence to the 2 mg Egrifta SV dose was established in pharmacokinetic bridging studies.

---

Subcutaneous Injection Protocol

All clinical trials administered tesamorelin via subcutaneous (SC) injection into the periumbilical abdomen — the same region where VAT accumulates. This is the only validated route.

Standard SC Injection Procedure

1. Site selection: Periumbilical abdomen, rotating injection sites systematically (e.g., left-to-right, ~2 cm from umbilicus minimum; never into the umbilicus itself)

2. Skin preparation: 70% isopropyl alcohol swab; allow 30 seconds to dry fully

3. Pinch technique: Pinch 1–2 inches of skin/fat between thumb and forefinger to elevate subcutaneous layer

4. Needle angle: 45–90 degrees depending on subcutaneous tissue depth; leaner subjects use 45°

5. Injection: Slow, steady depression of plunger over 5–10 seconds

6. Post-injection: Release pinch, withdraw needle, gentle pressure with gauze (do not rub — rubbing disperses the depot)

7. Site rotation log: Document each injection site to prevent local lipodystrophy at injection areas

Timing

• •FDA-approved protocol: Once daily, typically at bedtime
• •Rationale: Endogenous GH release is predominantly nocturnal; bedtime GHRH stimulation synergizes with the natural GH pulse window
• •Fasting window: Administer on an empty stomach (2+ hours post-prandial); dietary fat and carbohydrates can blunt GH response by raising somatostatin tone

---

Dosage Ranges from Clinical Trial Data

> The following data is derived from published peer-reviewed Phase III trials and the FDA-approved prescribing information. These figures reflect research observations and do not constitute dosing recommendations.

Phase III Trial Evidence (Falutz et al., NEJM 2007 + Grinspoon et al. extension)

The pivotal Phase III program enrolled 806 HIV-positive patients with antiretroviral-associated visceral adiposity across two parallel multicenter trials:

Key dose finding: All Phase III data used the 2 mg subcutaneous once-daily dose exclusively. No higher dose has been validated. Research protocols that have explored lower doses (1 mg/day) in non-HIV populations for tolerability report attenuated but measurable IGF-1 elevation, without head-to-head VAT efficacy data.

Dose Discontinuation / Regain Kinetics

Phase III extension data show:

• •Patients who discontinued tesamorelin at week 26 regained approximately 40–60% of lost VAT by week 52
• •Long-term continuation (18–24 months) maintained VAT reduction at ~18% plateau
• •On-off cycling has not been formally studied; the regain-on-cessation pattern mirrors GLP-1 receptor agonist discontinuation dynamics

---

Common Tesamorelin Research Study Designs

Published tesamorelin studies follow several recurring design templates that inform contemporary research protocols:

1. Parallel-Group, Placebo-Controlled VAT Studies (The Phase III Model)

Structure: 26- or 52-week randomized placebo-controlled trial; primary endpoint = change in VAT by CT cross-section at L4-L5

Dose: Tesamorelin 2 mg/day SC vs. matching placebo

Key measurements: VAT by CT, lean body mass by DEXA, fasting glucose, HbA1c, IGF-1, lipid panel

Canonical example: Falutz et al. (NEJM 2007), N=412 per arm

2. Extension / Withdrawal Studies (On-Off Kinetics)

Structure: After 26-week active phase, randomize responders to continue vs. switch to placebo for a further 26 weeks

Purpose: Characterize regain kinetics and whether cycling provides net benefit

Finding: ~40–60% VAT regain within 26 weeks of discontinuation — establishing that the effect is treatment-dependent, not disease-modifying

3. Liver Fat Studies (MASLD Model)

Structure: Sub-study nested within larger VAT trial; MRI-spectroscopy or MRI-PDFF for hepatic fat fraction (HFF)

Primary endpoint: HFF change at 12 months

Key example: PMC11365754 (2024): 31% relative HFF reduction vs. 0% placebo among INSTI-treated HIV patients

4. Cognitive / Neurological Studies

Structure: Smaller N (20–80), 6–12 months; paired with neuropsychiatric batteries (HVLT-R, BVMT-R)

Hypothesis: GH-axis normalization may modulate hippocampal IGF-1 signaling and neuroplasticity

Current status: Exploratory; no Phase III cognitive endpoint studies completed

5. Biomarker / Mechanistic Studies

Structure: Dose-ranging (0.5 mg, 1 mg, 2 mg/day) with dense PK/PD sampling

Endpoints: Plasma GH pulse profiles (frequent sampling q15 min for 4–12 h), serum IGF-1, IGFBP-3, lipase activity, adiponectin

Use case: When mechanistic GH-axis characterization is the primary goal rather than a clinical endpoint

---

Side Effects Observed in Research

> The following adverse events were observed in Phase III clinical trials and post-marketing surveillance of the FDA-approved Egrifta formulation. These findings are documented for scientific context only.

The tesamorelin Phase III program (N=806) generated the most comprehensive adverse event dataset for any GHRH analog in adults.

Common Adverse Events (≥5% incidence in clinical trials)

Metabolic Considerations

Blood glucose / insulin resistance: Tesamorelin reduces insulin sensitivity modestly. In Phase III trials, fasting glucose increased a mean +0.2 mmol/L (+3.6 mg/dL) vs. placebo. Subjects with pre-existing type 2 diabetes showed greater glucose elevation. Investigators monitoring metabolic parameters in long-term studies should track HbA1c alongside VAT measurements.

IGF-1 elevation: By design, tesamorelin elevates circulating IGF-1. In Phase III, mean IGF-1 increased from approximately 130 ng/mL to 200 ng/mL at steady state. Elevated IGF-1 is mechanistically expected — it is the primary GH-axis marker. Research protocols tracking GH-axis dynamics should baseline and serially measure IGF-1.

Fluid retention: GH-axis activation increases renal sodium reabsorption and promotes water retention. Peripheral edema (8.3% vs. 3.3% placebo) and carpal tunnel-like paresthesias (6.1%) are class effects shared across GHRH analogs and direct GH administration.

Injection Site Reactions

The most common adverse event (27.3%) is local injection site reaction — erythema, induration, pruritis, and/or pain at the periumbilical injection site. These reactions are typically mild-to-moderate, resolve without intervention, and decrease in frequency with consistent injection technique and site rotation. Investigators conducting repeated-measure studies should document site reactions as a secondary outcome.

Contraindication Flags (from Egrifta prescribing information)

• •Active malignancy: GHRH agonists are contraindicated in the presence of active neoplasia; GH-axis activation may theoretically stimulate IGF-1-dependent tumor growth
• •Pregnancy/lactation: Not studied; avoid
• •Hypersensitivity: History of hypersensitivity to tesamorelin, mannitol (excipient in Egrifta), or GHRH analogs
• •Pituitary pathology: Hypothalamic/pituitary disease may blunt or abolish response — confirm pituitary axis integrity before initiating research protocols

---

Comparison with Other GH Secretagogues

For researchers evaluating GHRH analogs, understanding the dosing distinctions between tesamorelin and sermorelin is essential:

The key mechanistic distinction: sermorelin's shorter half-life more closely mimics endogenous pulsatile GHRH secretion; tesamorelin's N-terminal modification produces a longer receptor residence time, which appears responsible for its superior visceral fat selectivity. Whether this selectivity is purely dose-driven or mechanistically unique remains an open research question.

See our Sermorelin Dosage Guide for parallel protocol documentation.

---

Storage and Stability

Unreconstituted Lyophilized Powder

• •Temperature: Refrigerated, 2–8°C (36–46°F)
• •Light exposure: Store in original carton; protect from light
• •Do not freeze
• •Shelf stability at labeled storage conditions: per manufacturer dating (typically 24–36 months)

Reconstituted Solution

• •Must be used immediately per prescribing information
• •If brief delay is unavoidable, maintain at 2–8°C; use within 3 hours
• •Do not store reconstituted solution for multi-day use (Egrifta SV/original)
• •Exception — Egrifta WR: Weekly-reconstituted vial is formulated for 7-day stability at 2–8°C once reconstituted

Research-Grade vs. Pharmaceutical-Grade Storage

For non-GMP research peptide material, investigators should verify certificate of analysis (CoA) for purity (>98% HPLC), endotoxin testing (<1 EU/mg), and sterility testing before use. Lyophilized peptide stability is generally longer than solution-phase; reconstitute immediately before each experiment.

---

Sourcing Tesamorelin for Research

When procuring tesamorelin for in vitro or pre-clinical research applications, researchers should evaluate suppliers on:

1. HPLC purity certificate: ≥98% area purity for research applications; ≥99% for GMP-comparable work

2. Mass spectrometry confirmation: ESI-MS or MALDI-TOF confirming correct molecular weight (MW: 5135.8 Da for tesamorelin free base)

3. Endotoxin quantification: LAL assay results; critical for cell-culture and animal work

4. Sterility testing: For any injected research use

5. Cold-chain documentation: Temperature logs confirming unbroken refrigeration during shipping

6. Lot-to-lot consistency: Relevant for longitudinal studies

Browse and compare verified tesamorelin suppliers on our Tesamorelin price comparison page — 179 supplier listings with purity tiers, pricing, and availability updated weekly.

---

Price Comparison

Research-grade tesamorelin pricing varies considerably across the supplier landscape. Key factors affecting price per mg:

• •Purity tier: 95% HPLC vs. 98%+ vs. GMP-grade
• •Quantity: Per-vial vs. bulk lyophilized orders
• •Endotoxin testing: Tested lots command a premium
• •Supplier certification: ISO 17025, GMP-certified facilities

Compare current supplier pricing and availability on the Peptides.SO compare tool — or go directly to the Tesamorelin supplier listings for 179 verified options.

---

RUO Disclaimers

This article is for Research Use Only.

• •Tesamorelin (Egrifta SV, Egrifta WR) is an FDA-approved prescription drug. Possession without a valid prescription is regulated under federal and applicable state law.
• •The FDA-approved indication for tesamorelin is HIV-associated lipodystrophy only. All other uses are off-label and require physician supervision.
• •The dosage protocols described in this article reflect published clinical trial data and are not recommendations for any individual's use outside a supervised medical or approved research context.
• •Researchers must comply with all applicable IRB/IACUC protocols and institutional biosafety requirements.
• •Peptides.SO does not sell, distribute, or compound tesamorelin or any other regulated substance. We provide research information and supplier comparison services only.

---

Key References

2. Grinspoon SK, et al. "Effects of an oral growth hormone secretagogue in adults with HIV infection." JAMA 2010. [Phase III extension data]

3. Stanley TL, et al. "Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial." JAMA 2014. PMID: 25038357

4. Theratechnologies/FDA. "Egrifta SV Prescribing Information." Updated 2024. accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf

5. Theratechnologies. "Egrifta WR FDA Approval, March 2025." (NDA supplement)

6. PMC11365754 — "Efficacy and Safety of Tesamorelin in People with HIV on Integrase Inhibitors." Open Forum Infectious Diseases 2024.

7. ID Week 2023 Poster — "Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV." Theratechnologies presentation.

---

For related reading, see our GHRH Analogs Compared overview and our Sermorelin Dosage Guide. Ready to compare supplier pricing? Visit the Tesamorelin supplier listings or use the Peptides.SO compare tool.